Advertisement

Topics

PharmaForce International: Majority of Physicians Say They Feel "Somewhat" or "Very" Comfortable in Prescribing a Biosimilar in Place of a Traditional Biologic

09:15 EDT 1 Aug 2017 | PR Newswire

READING, Pa., Aug. 1, 2017 /PRNewswire/ -- In an effort to gain a comprehensive understanding of the biosimilars marketplace, PFI interviewed personnel across multiple business functions including sales, marketing, strategy, medical affairs, market access, and reimbursement.

Lorrie Berg-Henne, Director of Marketing and Sales at PFI, says that awareness among physicians has risen over the past 2-3 years.

"Early adopter physicians who stay current with the medical literature, who take online CME courses, and who attend conferences are usually well aware of biosimilars," Berg-Henne said.

"However, there are a large number of 'wait and see' physicians who still remain relatively unaware of biosimilars, thus lowering the chance of these medicines being prescribed to patients."

Additional industry insight captured in this report will allow commercial pharmaceutical professionals to:

  1. Fine-tune their own biosimilar commercial operations initiatives by reviewing perceptions among physicians and payers
  2. Gain an understanding of hurdles to biosimilar market entry
  3. Understand the role of an effective managed care effort on biosimilar commercialization
  4. Discover the effect of discounting on biosimilar sales models
  5. See observed variations in biosimilar uptake across therapeutic areas

For more information on the report mentioned above, please contact Colton Dunkle at colton.dunkle@strategicreports.com or by phone at 610-370-0603.

PharmaForce International (PFI) is a competitive intelligence firm with over two decades of experience in the pharmaceutical and biotech industries. PFI has become the market leader in commercial operations benchmarking and competitive intelligence. The globally focused company employs marketplace experts uniquely qualified to perform primary research required by clients in most major pharmaceutical markets around the world, including Europe, India, Japan, Latin America, and the United States.

View original content with multimedia:http://www.prnewswire.com/news-releases/pharmaforce-international-majority-of-physicians-say-they-feel-somewhat-or-very-comfortable-in-prescribing-a-biosimilar-in-place-of-a-traditional-biologic-300497587.html

SOURCE PharmaForce International

NEXT ARTICLE

More From BioPortfolio on "PharmaForce International: Majority of Physicians Say They Feel "Somewhat" or "Very" Comfortable in Prescribing a Biosimilar in Place of a Traditional Biologic"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...